MEDINCELL S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.2 EUR | +3.65% |
|
-4.70% | +97.22% |
| 15/05 | Medincell: share price falls after disappointing clinical study | CF |
| 15/05 | Transcript : MedinCell S.A. - Special Call |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 13.96M 15.18M 1.26B | Sales 2025 * | 41.8M 45.47M 3.79B | Capitalization | 412M 449M 37.36B |
|---|---|---|---|---|---|
| Net income 2024 * | -23M -25.02M -2.08B | Net income 2025 * | 1M 1.09M 90.59M | EV / Sales 2024 * | 33 x |
| Net Debt 2024 * | 48.73M 53M 4.41B | Net Debt 2025 * | 58.83M 63.99M 5.33B | EV / Sales 2025 * | 11.3 x |
| P/E ratio 2024 * |
-15.5
x | P/E ratio 2025 * |
-266
x | Employees | 138 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.98% |
More Fundamentals
* Assessed data
More news
Latest transcript on MedinCell S.A.
More press releases
More news
| 1 day | +3.65% | ||
| 1 week | -4.70% | ||
| Current month | -1.11% | ||
| 1 month | +27.93% | ||
| 3 months | +62.84% | ||
| 6 months | +136.67% | ||
| Current year | +97.22% |
1 week
13.42
15.42
1 month
11.1017.50
Current year
6.9117.50
1 year
5.2517.50
3 years
4.7317.50
5 years
4.3520.00
10 years
4.3520.00
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Douat
CEO | Chief Executive Officer | 60 | 09/03/09 |
Stéphane Postic
DFI | Director of Finance/CFO | 50 | 01/23/01 |
| Chief Tech/Sci/R&D Officer | - | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sabri Markabi
BRD | Director/Board Member | - | 05/17/05 |
Tone Kvåle
BRD | Director/Board Member | 55 | 13/22/13 |
Virginie Lleu
BRD | Director/Board Member | - | 25/16/25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 14.2 | +3.65% | 119,450 |
| 16/24/16 | 13.7 | -5.91% | 200,824 |
| 15/24/15 | 14.56 | -4.21% | 382,354 |
| 14/24/14 | 15.2 | +1.33% | 69,134 |
| 13/24/13 | 15 | +0.67% | 177,473 |
Real-time Euronext Paris, May 17, 2024 at 09:05 pm IST
More quotes
MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable.
As of March 31, 2023, the company had a portfolio of 2 products in phase 3 clinical development and 6 products in preclinical development. Its most advanced product, mdc-IRM/UZEDYTM for the treatment of schizophrenia, has received marketing authorization in the United States.
Sector
Pharmaceuticals
Calendar
25/06/2024
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.2
EUR
Average target price
19.24
EUR
Spread / Average Target
+35.49%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +97.22% | 448M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- MEDCL Stock
